Gsk Share Discussion Threads

[netcurtains] 27/2/2021 09:36

Watfordhornet: Its a fall of 600 since its 2020 high.

That 600 is 50% of the current share price 1200!!!

Normally there would be some really bad bit of news to warrant a
fall of such MEGA proportions.

[watfordhornet] 27/2/2021 09:28

Ha - I know it's a drop but long way from having to do that

[roybel] 27/2/2021 09:24

At what stage do they have to release official news stating the reasons behind such a massive drop in share price ?

[royalalbert] 27/2/2021 08:46

Bought more yesterday, will carry on buying, looking to the future.

[coxsmn] 27/2/2021 08:33

Refer to the appendix slide pg 46 that accompanied the FY Results, it details out the costs and savings associated with the Separation Preparation Programme and the costs associated to prepare the Consumer business to operate as a stand alone.These are alongside other restructuring programmes that are also ongoing. In short, total charges related to the Separate Preparation Programme are expected to be £2.4bn (of which £1.5bn are cash payments). This programme is expected to achieve £800m in annual savings. The programme to ready the Consumer business for Separation includes one off charges of £600m (all of which are cash payments).

[careful] 26/2/2021 21:01

If the cost of split is $3bn and it saves $500m p.a. it is great business to do it.

Annual dividend costs that much, debt is cheap, cash flow high.
Think of it as an annuity paying 16% p.a.

They should have done it years ago, for once Woodford was correct.
the present business had become too cumbersome.

[mister md] 26/2/2021 18:58

Don't know why, but added more to holding today ...

[abdullla] 26/2/2021 18:54

Every body has a handicap mine is just taking the mickey for fun,yours is telling lies to satisfy your fantasies about owning,selling and shorting shares with perfect timings,whatever stay happy!

[abdullla] 26/2/2021 17:50

Sorry I cannot help it I just get a kick out of it !

[montyhedge] 26/2/2021 17:39

Keep taking the medication, I hope it's from GSK.It's a risk off day in the market. Have you seen the FTSE 100,reason US bond rise.They paid down debt 20% if you read the rns. We just had 23p dividend we got another 80p next 12 months, I hope they fall to 1150p next week, fill my boots.

[abdullla] 26/2/2021 17:09

God forbid!

[netcurtains] 26/2/2021 17:02

abdulla: Do you see the 'winding up' this year? Perhaps by the summer? Or earlier?

[abdullla] 26/2/2021 17:01

In the pecking order debt has to be paid first,in the current situation there will not be anything left for the share holders.

[watfordhornet] 26/2/2021 16:55

EW is - getting loads of free shares so of course she is holding

[abdullla] 26/2/2021 16:48

It will be sad to see this British jewel in the pharmas crown go to administration.

[netcurtains] 26/2/2021 16:39

Price now matches 2011 low and average price during 2007 2008 banking crash.

This is not just low.....
Its Marks and Spencer low

[eurofox] 26/2/2021 15:45

added 1196 - but that was hard

[essentialinvestor] 26/2/2021 15:35

IF markets continue to sell off and given the 12 month % decline
already in the GSK price, would expect some relative outperformance
against the wider UKX - no guarantees in the stock market though.

[spoole5] 26/2/2021 15:26

Did someone say this was a safe haven?!

[eurofox] 26/2/2021 14:54

added 1202

[coxsmn] 26/2/2021 14:30

European Regulator Recommends GlaxoSmithKline's Dostarlimab Approval

[montyhedge] 26/2/2021 13:02

Oh we wish 1000p, but we will never see it.

[essentialinvestor] 26/2/2021 12:46

Mark, I can't see £10, barring something completely left field.

However, a further 2021 FY guidance cut is possible, that already looks about
in the price fwiw - £11.50, may be, at a push.

[geckotheglorious] 26/2/2021 12:41

Despite Q4 2020 earnings misses, Vir's pipeline shows promise

In the pipeline, Vir says phase 2 trials for VIR-2482, its universal flu vaccine candidate under development with GlaxoSmithKline (NYSE:GSK), should begin in Q4 2021 after being delayed due to COVID-19.

In October, Vir began enrolling patients in a phase 3 study for VIR-7831 is a dual-action SARS-CoV-2 monoclonal antibody that has the potential to both block viral entry into healthy cells and clear infected cells. In December, the Company started a phase 3 NIH-sponsored trial evaluating VIR-7831 for hospitalized adults with COVID-19.
Vir shares closed down 1.4% to $64.49.